INNPF - Innocan Pharma posts positive results from CBD platform animal study

Innocan Pharma (INNPF) announces that a recent mice study showed that the company's CBD-loaded liposome platform technology ((LPT)) showed prolonged release of cannabidiol ((CBD)) into the bloodstream.The study showed the prolonged release of CBD into bloodstream lasted for at least 50 days following two injections.The company said that the results are significant in comparison to oral or inhalation-based intake methods, in which CBD is found to remain in the bloodstream for a maximum-period of 36 hours following a single dose.The technology may have a wide range of applications, such as epilepsy, pain relief, inflammation and central nervous system disorders.

For further details see:

Innocan Pharma posts positive results from CBD platform animal study